

37th ACS National Medicinal Chemistry Symposium

Confirmed Speakers

Session 1: Integrating Novel Chemical Modalities in Hit-to-lead: a New Paradigm for Early Drug Discovery

Discovery and Development of Macrocyclic Peptides for the Treatment of Complement-Mediated Disorders



Dr Susan ASHWELL
(UCB, Cambridge, United States)

Impact of Structure Based Drug Design in GPCR Lead Optimisation Strategies



Dr Miles CONGREVE
(SOSEI HEPTARES, Welwyn Garden City, United Kingdom)

Targeted Protein Degradation Strategies



Dr Chris DE SAVI
(KYMERA THERAPEUTICS, Watertown, United States)

Translating RNA Sequence into Lead Small Molecule Medicines



Prof. Matthew DISNEY
(SCRIPPS RESEARCH INSTITUTE, Jupiter, United States)

Structural Approach to Identify Lead Scaffolds for Protein-Protein Interaction Targets



Prof. Kyle HADDEN
(UNIVERSITY OF CONNECTICUT, Storrs, United States)

Integrating DNA-Encoded Library Technologies in Lead Discovery



Dr Lisa MARCAURELLE
(GSK, Cambridge, United States)

Session 2: New Directions in Targeting DNA Damage Repair (DDR)

M3541 and M4076: Discovery and Optimization of Potent and Selective ATM Kinase Inhibitors with Strong Anti-tumor Efficacy in Combination Therapies



Dr Thomas FUCHSS
(MERCK KGAA, Darmstadt, Germany)

Discovery of human DNA Polymerase theta (Pol?) Inhibitors



Dr Robert HEALD
(ARTIOS PHARMA LTD, Cambridge, United Kingdom)

37th ACS National Medicinal Chemistry Symposium

Confirmed Speakers

Title of talk to be confirmed

Dr Firoz JAIPURI
(IDEAYA BIOSCIENCES, San Francisco, United States)

Damage Incorporated: Discovery of ATR Inhibitor BAY 1895344 with Favorable PK Properties and Promising Anti-Tumor Efficacy in Monotherapy and Combination in Preclinical Tumor Models



Dr Ulrich LÜCKING
(FORX THERAPEUTICS, Basel, Switzerland)

The Modification of Pyrazolopyrimidinones and their Effect on WEE1 Inhibition and the DNA Damage Response



Prof. Phil REIGAN
(UNIVERSITY OF COLORADO, Aurora, United States)

Session 3: Hot Targets from NYC Academic and Biotech Scene

Designing and Combining Cancer's Off Switches



Dr Karen AKINSANYA
(SCHRODINGER, New York City, United States)

Rational Design of Inhibitors of Protein-Protein Interactions



Prof. Paramjit ARORA
(NYU, New York, United States)

Next Generation Drug Discovery



Dr Steve COLLETTI
(ZYMERGEN INC., New York, United States)

Optimization of Mycobacterium Tuberculosis (Mtb) Selective Inhibitors of Lipoamide Dehydrogenase (Lpd)



Dr John GINN
(TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, New York, United States)

Therapeutic Potential of the Gut-Brain Axis



Dr Iyassu SEBHAT
(KALLYOPE, New Jersey, United States)

Session 4: Targeting Autophagy for Cancer, Neurodegeneration, or Autoimmune Disease

Chasing Challenging Targets: Development of Selective Inhibitors of the Autophagy Pathway to Impact Cancer Therapy

37th ACS National Medicinal Chemistry Symposium

Confirmed Speakers



Prof. Leslie ALDRICH
(UNIVERSITY OF ILLINOIS AT CHICAGO, Chicago, United States)

Title of talk to be confirmed



Dr Peter FULLER
(MERCK & CO. INC., Boston, United States)

Chemical Activation of Chaperone-Mediated Autophagy for Protection against Neurodegeneration



Prof. Eviropidis GAVATHIOTIS
(ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, United States)

Activating PTEN-Induced Kinase 1 (PINK1) for Parkinson's Disease



Dr Nicholas HERTZ
(MITOKININ INC, San Francisco, United States)

Unraveling Autophagy in Cancer Using Chemical Genetics



Prof. Jeff MACKEIGAN
(MICHIGAN STATE UNIVERSITY, East Lansing, United States)

Session 5: Next Generation Therapies Shaped by Clinical Data

Discovery of LPA1 antagonists for the treatment of Pulmonary Fibrotic Diseases



Dr Peter CHENG
(BRISTOL-MYERS SQUIBB R & D, Hopewell, United States)

Discovery of Risdiplam, a Medicine for the Treatment of Spinal Muscular Atrophy



Dr Hasane RATNI
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)

Evolution of Clinical PI3K Inhibitors at Genentech



Dr Steve STABEN
(GENENTECH, South San Francisco, United States)

The Invention of MK-8262, a CETP Inhibitor for the Treatment of Coronary Heart Disease



Dr Petr VACHAL
(MERCK & CO. INC (MSD), Kenilworth, United States)

37th ACS National Medicinal Chemistry Symposium

Confirmed Speakers

Session 6: Lessons from Drug Hunters across Academia, NPOs and the Pharmaceutical Industry

Discovery of Nix-TB as a Novel Regimen that Significantly Shortens Treatment of Tuberculosis



Dr Christopher B. COOPER
(TB ALLIANCE, GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, New York, United States)

Discovery of Upadacitinib: a Tricyclic Janus Kinase 1 (JAK1) Inhibitor



Dr Kristine E. FRANK
(ABBVIE, North Chicago, United States)

Discovery of PAC-1 as a Procaspace-3 Activator and Anticancer Drug



Prof. Paul J. HERGENROTHER
(UNIVERSITY OF ILLINOIS, Urbana, United States)

From Concept to Clinic: the Story of M1 and mGlu4 Positive Allosteric Modulators (PAMs)



Prof. Craig LINDSLEY
(VANDERBILT UNIVERSITY, Nashville, United States)

Discovery of Fenebrutinib (rBTK) for the Treatment of Autoimmune Disorders



Dr Wendy YOUNG
(MPM CAPITAL POWERING BREAKTHROUGHS IN LIFE SCIENCES, Brisbane, United States)

Award Session

2022 Division of Medicinal Chemistry Award Lecture

2022 IUPAC-Richter Prize Lecture